Leukapheresis products market is expected to reach USD 27.1 million at a CAGR 7.8% during the forecast period 2023-2032. Leukapheresis is a blood therapy that removes aberrant white blood cells (WBCs).
Leukemia can be treated using leukapheresis, or it can be utilized as the initial stage in CAR T-cell therapy. The rising number of blood donors, the rising prevalence of leukemia, and the demand for leukapheresis products in clinical trials are all expected to drive the market forward. The high cost of therapeutic leukapheresis, a scarcity of qualified experts, and strict donor recruitment requirements, on the other hand, may limit market expansion over the projection period. Despite its therapeutic potential, leukapheresis is currently a rare treatment option, especially for hyperleukocytosis leukemia.
January 2023: Sanguine Biosciences, a pioneer in the connection of patients with biopharmaceutical companies to expedite precision medicine R&D and Cell & Gene Therapy, today announced a new investment from BroadOak Capital Partners, LLC, a prominent direct investment and advisory firm that specializes in life science research tools, pharmaceutical services, and diagnostics. Sanguine's laboratory operations, leukapheresis offerings, and patient donor network are all enhanced by the partnership with BroadOak.
Sanguine introduced a new apheresis product family in October 2022, which offers researchers a substantial quantity of immune and hematopoietic stem cells from single donors with confirmed disease. The offering addresses a significant unmet need in the field of life science research and development, with a particular emphasis on the high-growth and high-impact cell and gene therapy sector. Biopharmaceutical researchers employ human biospecimens for biomarker development, which can result in innovative clinical applications as a result of the translation of bench discoveries into bedside treatments for patients.
However, the procurement and processing of pertinent patient samples for research purposes are complicated by the complexity of biologic- and cell-based therapies. Through partnerships with patient advocacy groups and a comprehensive recruitment apparatus, Sanguine Biosciences simplifies this process and provides researchers with access to a diverse, nationwide network of over 60,000 patient donors.
February 2021: Lonza has expanded its renowned human primary cell offerings with the introduction of high-quality cryopreserved Leukopaks that are entirely customizable. Leukopaks that are frozen will facilitate the long-distance shipment of leukapheresis products without the potential for diminished cell viability that is a concern with fresh Leukopaks. The cryopreserved Leukopaks are designed for long-term storage in research laboratories, and they also provide immediate access to viable cells, thereby enhancing workflow flexibility and convenience. The cryopreserved Leukopaks are available in a variety of sizes, and a distinctive costing structure enables customers to only pay for the customization that is required.
Additionally, customers have access to a variety of donor characteristics and testing options. A Leukopak is a product that is enriched through leukapheresis and contains high concentrations of peripheral blood mononuclear cells, including T cells, B cells, and monocytes. Before progressing to full clinical manufacturing, these cells are a critical raw material in immunotherapy research and for optimizing the development of the cell therapy process. Nevertheless, it can be challenging to obtain fresh Leukopaks and they must be used promptly to prevent cell degradation.
Therapeutic leukapheresis in the treatment of pediatric patients, on the other hand, is becoming a hot topic among industry participants. This is primarily due to the negative effects and hazards of traditional treatments for children, such as chemotherapy. Leukapheresis can be used to treat or remove excess WBCs in children with lymphoma, as well as to collect stem cells from children for other cancer patients. The possibilities and benefits of leukapheresis in this application make it a market focus, especially as only a few hospitals in both developed and emerging economies presently provide leukapheresis treatment for children.
The leukapheresis products market has been segmented into type, application, and end user.
On the basis of type, the market has been segmented into leukapheresis devices and leukapheresis disposables. The leukapheresis devices segment has been segmented into apheresis devices, leukapheresis column & cell separators, and leukoreduction filters.
The market, on the basis of application, has been segmented into research applications and therapeutic applications.
On the basis of end user, the market has been segmented into blood component providers and blood centers, hospitals and transfusion centers, and others.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The leukapheresis products market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European leukapheresis products market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The leukapheresis products market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The leukapheresis products market in the Middle East & Africa has been segmented into the Middle East and Africa.
some of the key players in the leukapheresis products market are
Regional Market Summary
Geographically, the Americas is anticipated to dominate the leukapheresis products market owing to the growing number of blood donations, rising incidence and prevalence of leukaemia and growing demand for leukopaks in clinical research. According to the America’s Blood Centers, more than 15 million pints of blood are transfused in the US each year.
Europe is expected to hold the second largest position in the leukapheresis products market. The market growth in this region is attributed to the increasing prevalence of leukemia and well-developed healthcare sector in the region. According to the Cancer Research UK, about 9,900 new cases of leukaemia were reported in UK in 2015.
The leukapheresis products market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. The Asia-Pacific region is expected to be fastest growing region owing to the increase in regenerative medicine research in the region, growth in the number of clinical trials for CAR-T therapy, and the increasing presence of major multinational pharma and biotech companies, and improvement in healthcare access.
The Middle East & Africa has the lowest share of the leukapheresis products market. Majority of the market of the region is anticipated to be held by the Middle East region owing to the growing government initiatives for the healthcare sector.
Recent Development
Intended Audience
| Report Attribute/Metric | Details |
| Â Â Market Size | USD 27.1 Million |
| Â Â CAGR | Â Â 7.8% (2023-2032) |
| Â Â Base Year | Â Â 2019 |
| Â Â Forecast Period | Â Â 2023-2032 |
| Â Â Historical Data | Â Â 2018 |
| Â Â Forecast Units | Â Â Value (USD Million) |
| Â Â Report Coverage | Â Â Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Â Â Segments Covered | Â Â Type, Application and End user |
| Â Â Geographies Covered | Â Â North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Â Â Key Vendors | Â Â Haemonetics, Terumo BCT, Asahi Kasei Medical, STEMCELL Technologies, Macopharma, HemaCare Corporation, Caltag Medsystem, ALLCells, LLC, ZENBIO, Fresenius Kabi, PPA Research Group, StemExpress and others |
| Â Â Key Market Opportunities | Â Â New product launches and R&D Amongst major key Players |
|   Key Market Drivers | · Growing number of blood donations Increasing prevalence of leukaemia · Demand for leukapheresis products in clinical researc |
Leukapheresis Products Market Highlights:
Frequently Asked Questions (FAQ) :
The leukapheresis products market is projected to grow at a 7.8% CAGR between 2023-2032.
The Americas is projected to command the largest share in the leukapheresis products market.
Rising prevalence of leukemia is boosting market growth.
High cost may limit market growth.
Different strategies used by market players to create a dominance in the leukapheresis products market include product launches, collaborations, strategic alliances, and others.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
